Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.

Oligonucleotide probes are short stretches of single-stranded DNA or RNA used to detect the presence of complementary nucleic acid sequences (target sequences) by hybridization. Oligonucleotide ...

Researchers designed oligopeptides that could co-assemble with therapeutic cargoes to create nanoparticles that improved the ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.